达雷妥尤单抗联合化疗治疗CD38<sup>+</sup>急性白血病2例报告并文献复习

钱娟; 王菲; 王信峰; 林赠华; 黄红铭

doi:10.13201/j.issn.1004-2806.2023.09.012

达雷妥尤单抗联合化疗治疗CD38⁺急性白血病2例报告并文献复习

- 南通大学附属医院血液科(江苏南通，226001)
基金项目:
南通市科技项目(No：JCZ21030)；2020年度南通大学附属医院教学研究课题(No：Tfj20003)

详细信息

通讯作者: 黄红铭，E-mail：hhmmmc@163.com

中图分类号: R733.71

收稿日期: 2022-10-18

刊出日期: 2023-09-01

Daratumumab combined with chemotherapy in the treatment of CD38⁺ acute leukemia: a report of 2 cases and literature review

- Department of Hematology, Affiliated Hospital of Nantong University, Nantong, 226001, China

More Information

Corresponding author: HUANG Hongming, E-mail: hhmmmc@163.com

Received Date: 18 October 2022

Publish Date: 01 September 2023

摘要

摘要: 目的探讨达雷妥尤单抗联合化疗治疗难治CD38阳性急性白血病患者的疗效及安全性。方法回顾性分析2022年1月—3月在南通大学附属医院血液科收治的2例患者，其中1例near-ETP-ALL，另1例急性髓系白血病(M5)，均难治，且CD38阳性，分析其临床诊疗经过，并进行文献复习。结果 2例CD38阳性的急性白血病患者经多线治疗后均未达完全缓解，后调整治疗方案，获得微小残留病灶阴性，能耐受治疗，未出现严重的不良反应，其中1例顺利完成异基因造血干细胞移植。结论达雷妥尤单抗联合化疗为难治急性白血病患者提供了一种新的治疗手段，其安全有效，值得临床进一步探讨。
- 难治 /
- 急性白血病 /
- 达雷妥尤单抗 /
- 微小残留病灶
Abstract: Objective To investigate the efficacy and safety of daratumumab combined with chemotherapy in the treatment of refractory CD38 positive acute leukemia patients.Methods Retrospective analysis was made on 2 patients admitted to the Hematology Department of the Affiliated Hospital of Nantong University from January to March 2022, including one near-ETP-ALL and the other acute myeloid leukemia(M5), all of whom were refractory, and CD38⁺. The clinical diagnosis and treatment process were analyzed and the literature was reviewed.Results Two patients with CD38⁺acute leukemia did not achieve complete remission after multi-line treatment. After adjusting the treatment regimen, they obtained negative minimal residual disease and were able to tolerate the treatment without serious adverse events. One case had successfully completed allogeneic hematopoietic stem cell transplantation.Conclusion Daratumumab combined with chemotherapy provides a new treatment method for patients with refractory acute leukemia, which is safe and effective, and is worthy of further clinical discussion.
- refractory /
- acute leukemia /
- daratumumab /
- minimal residual disease

HTML全文

参考文献(24)

[1]	龚敏, 吴迪, 李秋柏, 等. 维奈克拉治疗急性髓系白血病的疗效与安全性的单中心真实世界研究[J]. 临床血液学杂志, 2022, 35(5): 359-363. https://lcxy.whuhzzs.com/article/doi/10.13201/j.issn.1004-2806.2022.05.012
[2]	Adamska M, Kowal-Wisniewska E, Przybyłowicz-Chalecka A, et al. Clinical outcomes of therapy-related acute myeloid leukemia: an over 20-year single-center retrospective analysis[J]. Pol Arch Intern Med, 2023, 133(1): 1-36.
[3]	Pommert L, Tarlock K. The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies[J]. Hematology, 2022, 2022(1): 603-610. doi: 10.1182/hematology.2022000358
[4]	Bohl SR, Bullinger L, Rücker FG. New targeted agents in acute myeloid leukemia: new hope on the rise[J]. Int J Mol Sci, 2019, 20(8): E1983. doi: 10.3390/ijms20081983
[5]	中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会白血病淋巴瘤学组. 中国成人急性淋巴细胞白血病诊断与治疗指南(2021年版)[J]. 中华血液学杂志, 2021, 42(9): 705-716. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXZ202203002.htm
[6]	中华医学会血液学分会白血病淋巴瘤学组. 中国复发难治性急性髓系白血病诊疗指南(2021年版)[J]. 中华血液学杂志, 2021, 42(8): 624-627.
[7]	Richard S, Jagannath S, Cho HJ, et al. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma[J]. Expert Rev Hematol, 2021, 14(1): 31-45. doi: 10.1080/17474086.2021.1858790
[8]	Amaador K, Vos JMI, Pals ST, et al. Discriminating between Waldenstr m macroglobulinemia and marginal zone lymphoma using logistic LASSO regression[J]. Leuk Lymphoma, 2022, 63(5): 1070-1079. doi: 10.1080/10428194.2021.2018584
[9]	Salles G, Gopal AK, Minnema MC, et al. Phase 2 study of daratumumab in relapsed/refractory mantle-cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma[J]. Clin Lymphoma Myeloma Leuk, 2019, 19(5): 275-284. doi: 10.1016/j.clml.2018.12.013
[10]	Vakrmanová B, Nováková M, íha P, et al. CD38: a target in relapsed/refractory acute lymphoblastic leukemia-limitations in treatment and diagnostics[J]. Pediatr Blood Cancer, 2022, 69(9): e29779.
[11]	Farber M, Chen YY, Arnold L, et al. Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis[J]. Sci Rep, 2021, 11(1): 22062. doi: 10.1038/s41598-021-01300-8
[12]	Mistry JJ, Moore JA, Kumar P, et al. Daratumumab inhibits acute myeloid leukaemia metabolic capacity by blocking mitochondrial transfer from mesenchymal stromal cells[J]. Haematologica, 2021, 106(2): 589-592.
[13]	Bride KL, Vincent TL, Im SY, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia[J]. Blood, 2018, 131(9): 995-999. doi: 10.1182/blood-2017-07-794214
[14]	Mirgh S, Ahmed R, Agrawal N, et al. Will Daratumumab be the next game changer in early thymic precursor-acute lymphoblastic leukaemia?[J]. Br J Haematol, 2019, 187(2): e33-e35.
[15]	Zhang YP, Xue S, Liu FH, et al. Daratumumab for quick and sustained remission in post-transplant relapsed/refractory acute lymphoblastic leukemia[J]. Leuk Res, 2020, 91: 106332.
[16]	Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20): 2391-2405.
[17]	Stengel A, Kern W, Haferlach T, et al. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases[J]. Leukemia, 2017, 31(3): 705-711.
[18]	Barajas S, Cai WJ, Liu Y. Role of p53 in regulation of hematopoiesis in health and disease[J]. Curr Opin Hematol, 2022, 29(4): 194-200.
[19]	Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease[J]. Science, 2019, 366(6465): eaan4673.
[20]	Cluzeau T, Sebert M, Rahmé R, et al. Eprenetapopt plus azacitidine in TP 53 -mutated myelodysplastic syndromes and acute myeloid leukemia: a phase Ⅱ study by the groupe francophone des myélodysplasies(GFM)[J]. J Clin Oncol, 2021, 39(14): 1575-1583.
[21]	Michaleas S, Penninga E, Hovgaard D, et al. EMA review of daratumumab(darzalex)for the treatment of adult patients newly diagnosed with multiple myeloma[J]. Oncologist, 2020, 25(12): 1067-1074.
[22]	Nahi H, Chrobok M, Gran C, et al. Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma[J]. PLoS One, 2019, 14(2): e0211927.
[23]	张警丹, 李鹏, 李强, 等. 抗CD38单克隆抗体对多发性骨髓瘤患者交叉配血干扰及输血疗效的影响[J]. 临床血液学杂志, 2022, 35(8): 539-542. https://lcxy.whuhzzs.com/article/doi/10.13201/j.issn.1004-2806.2022.08.001
[24]	Lancman G, Arinsburg S, Jhang J, et al. Blood transfusion management for patients treated with anti-CD38 monoclonal antibodies[J]. Front Immunol, 2018, 9: 2616.